Wild D - Search Results

1

First clinical evidence that imaging with somatostatin receptor antagonists is feasible.

Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, Maecke HR, Weber WA. Wild D, et al. J Nucl Med. 2011 Sep;52(9):1412-7. doi: 10.2967/jnumed.111.088922. Epub 2011 Aug 18. J Nucl Med. 2011. PMID: 21852357 Free article.

2

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. Wild D, et al. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47. doi: 10.1007/s00259-003-1255-5. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937948

3

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.

Wild D, Mäcke HR, Waser B, Reubi JC, Ginj M, Rasch H, Müller-Brand J, Hofmann M. Wild D, et al. Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):724. doi: 10.1007/s00259-004-1697-4. Eur J Nucl Med Mol Imaging. 2005. PMID: 15551131 No abstract available.

4

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC. Ginj M, et al. Among authors: wild d. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41. doi: 10.1073/pnas.0607761103. Epub 2006 Oct 20. Proc Natl Acad Sci U S A. 2006. PMID: 17056720 Free PMC article.

5

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR. Wild D, et al. J Nucl Med. 2006 Dec;47(12):2025-33. J Nucl Med. 2006. PMID: 17138746 Free article.

6

DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.

Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR. Zhang H, et al. Among authors: wild d. Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1198-208. doi: 10.1007/s00259-006-0347-4. Epub 2007 Jan 30. Eur J Nucl Med Mol Imaging. 2007. PMID: 17262215 Free article.

7

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G. Wicki A, et al. Among authors: wild d. Clin Cancer Res. 2007 Jun 15;13(12):3696-705. doi: 10.1158/1078-0432.CCR-06-2965. Clin Cancer Res. 2007. PMID: 17575235

8

New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.

Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC, Maecke HR. Ginj M, et al. Among authors: wild d. Clin Cancer Res. 2008 Apr 1;14(7):2019-27. doi: 10.1158/1078-0432.CCR-07-1687. Clin Cancer Res. 2008. PMID: 18381940

9

Glucagon-like peptide 1-receptor scans to localize occult insulinomas.

Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Wild D, et al. N Engl J Med. 2008 Aug 14;359(7):766-8. doi: 10.1056/NEJMc0802045. N Engl J Med. 2008. PMID: 18703486 No abstract available.

10

Glucagon-like peptide-1 receptor imaging for localization of insulinomas.

Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, Gloor B, Martius F, Maecke H, Reubi JC. Christ E, et al. Among authors: wild d. J Clin Endocrinol Metab. 2009 Nov;94(11):4398-405. doi: 10.1210/jc.2009-1082. Epub 2009 Oct 9. J Clin Endocrinol Metab. 2009. PMID: 19820010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

618 results

Search Page

Filters